NCT05060848Active, not recruiting
Plasma Hydrogen Sulfide as a Biomarker for Alzheimer's Disease and Related Dementias
Source: ClinicalTrials.gov · Last updated 8 Mar 2023
Brief summary (registry, in English)
Hydrogen sulfide is a signaling molecule that is important for vascular health. Because vascular factors such as hypertension and high cholesterol are risk factors for Alzheimer's disease and related dementias, we hypothesize that hydrogen sulfide plays an important role in brain health as well. We will compare blood levels of hydrogen sulfide across groups of people with and without dementia. We will also look at the relationship between hydrogen sulfide, cognitive dysfunction and measures of brain microvascular disease examine the contribution of hydrogen sulfide to cognitive decline. Our goal is to identify a biomarker of vascular dysfunction in dementia.
- Status (registry)
- Active, not recruiting
- Study type
- Observational
- Enrollment
- 100 (estimated)
- First submitted
- 20 Sept 2021
- Start date
- 1 Apr 2021
- Primary completion date
- 31 May 2026
- Lead sponsor
- Louisiana State University Health Sciences Center Shreveport
- Diseases
- Alzheimer disease
- NCT number
- NCT05060848
What you commit to
- Study type: Observational
- Planned participants: 100
- From 1 Apr 2021 to the primary completion date, 31 May 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Exclusion criteria are history of significant neurologic disease or mental illness, unstable medical conditions that could interfere with completion of study, substance abuse within 2 years, contraindications to MRI, abnormal findings on MRI, history of chronic kidney disease, and investigational agents within 1 month of participation.
Who the study is looking for
- All participants must be aged \>55 years with English as the 1⁰ language, with stable permitted medications for \<4 weeks, geriatric depression scale score \<6, visual and auditory acuity adequate to perform tests, and history of education excluding developmental cognitive abnormalities.
Age in the registry: 55 years to 100 years · Sex: All · Accepts healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| LSU Health Shreveport Center for Brain Health Coordinator of this site? Confirm its status | Shreveport | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.